The therapeutic potential of TREM2 in cancer
Cancer continues to be a substantial health concern and a leading cause of death in the United States and around the world. Therefore, it is important to continue to explore the potential of novel therapeutic targets and combinatorial therapies. Triggering receptor expressed on myeloid cells 2 (TREM...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.984193/full |
| _version_ | 1828136892220047360 |
|---|---|
| author | Elysa M. Wolf Barbara Fingleton Alyssa H. Hasty Alyssa H. Hasty |
| author_facet | Elysa M. Wolf Barbara Fingleton Alyssa H. Hasty Alyssa H. Hasty |
| author_sort | Elysa M. Wolf |
| collection | DOAJ |
| description | Cancer continues to be a substantial health concern and a leading cause of death in the United States and around the world. Therefore, it is important to continue to explore the potential of novel therapeutic targets and combinatorial therapies. Triggering receptor expressed on myeloid cells 2 (TREM2) is a transmembrane receptor of the immunoglobulin superfamily that associates with DNAX activation protein (DAP) 12 and DAP10 to propagate signals within the cell. TREM2 has primarily been recognized for its expression on cells in the monocyte-macrophage lineage, with the majority of work focusing on microglial function in Alzheimer’s Disease. However, expansion of TREM2 research into the field of cancer has revealed that epithelial tumor cells as well as intratumoral macrophages and myeloid regulatory cells also express TREM2. In this review, we discuss evidence that TREM2 contributes to tumor suppressing or oncogenic activity when expressed by epithelial tumor cells. In addition, we discuss the immunosuppressive role of TREM2-expressing intratumoral macrophages, and the therapeutic potential of targeting TREM2 in combination with immune checkpoint therapy. Overall, the literature reveals TREM2 could be considered a novel therapeutic target for certain types of cancer. |
| first_indexed | 2024-04-11T18:11:05Z |
| format | Article |
| id | doaj.art-acd772eea8e54e10b62b393d69809642 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T18:11:05Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-acd772eea8e54e10b62b393d698096422022-12-22T04:10:07ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-09-011210.3389/fonc.2022.984193984193The therapeutic potential of TREM2 in cancerElysa M. Wolf0Barbara Fingleton1Alyssa H. Hasty2Alyssa H. Hasty3Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, United StatesDepartment of Pharmacology, Vanderbilt University, Nashville, TN, United StatesDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, United StatesVeterans Affairs Tennessee Healthcare System, Nashville, TN, United StatesCancer continues to be a substantial health concern and a leading cause of death in the United States and around the world. Therefore, it is important to continue to explore the potential of novel therapeutic targets and combinatorial therapies. Triggering receptor expressed on myeloid cells 2 (TREM2) is a transmembrane receptor of the immunoglobulin superfamily that associates with DNAX activation protein (DAP) 12 and DAP10 to propagate signals within the cell. TREM2 has primarily been recognized for its expression on cells in the monocyte-macrophage lineage, with the majority of work focusing on microglial function in Alzheimer’s Disease. However, expansion of TREM2 research into the field of cancer has revealed that epithelial tumor cells as well as intratumoral macrophages and myeloid regulatory cells also express TREM2. In this review, we discuss evidence that TREM2 contributes to tumor suppressing or oncogenic activity when expressed by epithelial tumor cells. In addition, we discuss the immunosuppressive role of TREM2-expressing intratumoral macrophages, and the therapeutic potential of targeting TREM2 in combination with immune checkpoint therapy. Overall, the literature reveals TREM2 could be considered a novel therapeutic target for certain types of cancer.https://www.frontiersin.org/articles/10.3389/fonc.2022.984193/fullTREM2 (triggering receptor expressed on myeloid cells 2)immunotherapytumor associated macrophage (TAM)immunosuppressiontumor infiltrating lymphocyte (TIL) |
| spellingShingle | Elysa M. Wolf Barbara Fingleton Alyssa H. Hasty Alyssa H. Hasty The therapeutic potential of TREM2 in cancer Frontiers in Oncology TREM2 (triggering receptor expressed on myeloid cells 2) immunotherapy tumor associated macrophage (TAM) immunosuppression tumor infiltrating lymphocyte (TIL) |
| title | The therapeutic potential of TREM2 in cancer |
| title_full | The therapeutic potential of TREM2 in cancer |
| title_fullStr | The therapeutic potential of TREM2 in cancer |
| title_full_unstemmed | The therapeutic potential of TREM2 in cancer |
| title_short | The therapeutic potential of TREM2 in cancer |
| title_sort | therapeutic potential of trem2 in cancer |
| topic | TREM2 (triggering receptor expressed on myeloid cells 2) immunotherapy tumor associated macrophage (TAM) immunosuppression tumor infiltrating lymphocyte (TIL) |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.984193/full |
| work_keys_str_mv | AT elysamwolf thetherapeuticpotentialoftrem2incancer AT barbarafingleton thetherapeuticpotentialoftrem2incancer AT alyssahhasty thetherapeuticpotentialoftrem2incancer AT alyssahhasty thetherapeuticpotentialoftrem2incancer AT elysamwolf therapeuticpotentialoftrem2incancer AT barbarafingleton therapeuticpotentialoftrem2incancer AT alyssahhasty therapeuticpotentialoftrem2incancer AT alyssahhasty therapeuticpotentialoftrem2incancer |